N/A
Completed N=39
Comparison of Endotracheal Intubation Over the Aintree Via the I-gel and Laryngeal Mask Airway Supreme
Difficult Intubation
Source: ClinicalTrials.gov NCT02476565 ↗
Enrolled (actual)
39
Serious AEs
0.0%
Results posted
Jan 2018
Primary outcomePrimary: Time to Successful Tracheal Intubation — 197; 304 seconds
Summary
The investigators plan to conduct a randomized trial comparing the efficacy of intubating the tracheal using an Aintree intubation catheter through either the LMA-S or I-gel supraglottic devices
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Time to Successful Tracheal Intubation |
197; 304 | — |
| SECONDARY Time to Placement of the Supra Glottic Device |
155; 301 | — |
| SECONDARY Percent of Subjects Who Required 0, 1, 2, and 3 Airway Manipulations for the Placement of the Supraglottic Device |
80; 80; 10; 13; 5; 7 | — |
| SECONDARY Time to Placement of the Aintree Airway Intubation Catheter |
155; 301 | — |
| SECONDARY Percent of Subjects Who Required 0, 1, 2, 3 and 6 Airway Manipulations for the Placement of the Aintree. |
67; 25; 33; 25; 0; 31 | — |
| SECONDARY Time to Placement of the Endotrotracheal Tube |
81; 96 | — |
| SECONDARY Percent of Subjects With 0, 1, 2 and 3 Airway Manipulations Required for Placement of Endotrachial Tube |
67; 57; 17; 43; 11; 0 | — |
Eligibility Criteria
Inclusion Criteria
- Subjects that will require routine endotracheal intubation for general anesthesia as part of their surgery.
- Age >18 years old.
- Can provide informed consent.
Exclusion Criteria
- Subjects that require rapid sequence induction for endotracheal intubation; i.e., parturients, or any subject that is at high risk for aspirating gastric contents into the airway.
- Subjects that have an allergy to Propofol or eggs.
- Subjects that have an allergy to rocuronium.
- Subjects with a history of oropharyngeal or laryngeal surgery, or subjects undergoing oropharyngeal or laryngeal surgery.
- Subjects with congenital or anatomical airway anomalies.
- Subjects with anticipated reduced functional residual capacity as predicted by a body mass index ≥40.
- Currently enrolled in another research study.
Data sourced from ClinicalTrials.gov (NCT02476565). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.